Current recommendations state that HPV DNA testing may be used in conjunction with a Pap in women over 30, to follow patients with previous positive high-risk HPV screening results, or when Pap results are uncertain. Analysts have estimated the current domestic market for diagnostic preventative testing at approximately $600-700 million.
About Quantovir AB
Founded in 2001, Quantovir AB was formed as a natural continuation of years of research and development by Professor Ulf Gyllensten and his team at the department of Genetics and Pathology at the Rudbeck Laboratory, Uppsala University. Today, Quantovir AB is owned by Innovationsbron I Uppsala AB, Uppsala Universitets Holdingbolag UUAB together with a research group led by Professor Ulf Gyllensten at the Rudbeck Laboratory in Uppsala.
Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand
molecular diagnostics company that develops, manufactures, and markets
fully-integrated systems for genetic analysis in the clinical, industrial
and biothreat markets. The Company's systems enable rapid, sophisticated
genetic testing for organisms and genetic-based diseases by automati
Copyright©2007 PR Newswire.
All rights reserved